Hangzhou YiwenSai Biotechnology Co., Ltd. was established in 2009 and is a high-tech enterprise in China engaged in endometrial stem cell storage, research, and industrialization operations. In 2010, YiwenSai moved into the 'Hangzhou Science and Technology Innovation Incubator' and was selected as one of Hangzhou's first batch of Young Eagle Enterprises. Since its establishment, the company has worked closely with the U.S. stem cell listed company Cryo-Cell, the Zhejiang-California International Nanosystems Institute, the Guangzhou Institutes of Biomedicine and Health of the Chinese Academy of Sciences, and the Affiliated * Hospital and the Second Affiliated Hospital of Zhejiang University School of Medicine, among others, to jointly establish stem cell clinical research platforms. In strong partnership with the Tianjin International Joint Academy of Biomedicine, it established the 'Tianjin International Joint Academy of Biomedicine Zhejiang Applied Cell Technology Engineering Center', focusing on research into industry standards for clinical stem cell applications. In 2011, the company was awarded the title of 'Hangzhou High-Tech Enterprise', established a 'High-Tech Enterprise Technology R&D Center', and set up an 'Academician and Expert Workstation'. It introduced Academician Li Lanjuan of the Chinese Academy of Engineering as the company's chief scientist and signed the project 'Basic and Clinical Application Research on Endometrial Stem Cells in the Treatment of Liver Cirrhosis'. It also introduced Academician Zhao Guoping of the Chinese Academy of Engineering, Executive Director of the National Human Genome Center in Southern China, to provide technical guidance for the project 'Biological Identification of Endometrial Stem Cells and Comparative Functional Genomics Research on Mesenchymal Stem Cells from Different Sources'. With the help of the academicians' advanced scientific theories and technological achievements, YiwenSai has strengthened its core competitiveness, built technology platforms for storage, research, and industrialization, and formed a relatively complete system of standards related to cell operations. In the future, YiwenSai will strengthen the construction of a life bank, which is urgently needed in the stem cell industrialization process, accelerate the pace of clinical cell applications, better contribute to the development of the pharmaceutical industry in Zhejiang Province, and make effective contributions to the major development of China's health undertakings.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows